Company Focus
Alnylam Pharmaceuticals
Latest Alnylam Pharmaceuticals News
Pharmaceutical
Alnylam has secured expanded UK regulatory approval for Amvuttra (vutrisiran), broadening its indication to include treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults. 16 July 2025
Related News
Insights
Company Spotlight
USA-based KalVista Pharmaceuticals is a protease inhibitor specialist.
Latest News & Features of interest to Alnylam Pharmaceuticals
Pharmaceutical
French ophthalmology company Nicox has signed an agreement with Japan’s Kowa Company. 17 July 2025
Pharmaceutical
The Bristol Myers Squibb-Pfizer Alliance today announced a new direct-to-patient option for purchasing Eliquis (apixaban) via their Alliance’s patient resource Eliquis 360 Support. 17 July 2025
Biosimilars
South Korea’s Samsung Bioepis today announced it has entered into a license, development and commercialization agreement (DCA) with Harrow, for Samsung Bioepis’ ophthalmology portfolio. 17 July 2025
Pharmaceutical
Swiss pharma giant Novartis this morning reported second quarter 2025 financial results, showing that net sales were $14.1 billion (+12%, +11% cc), with volume contributing 12 percentage points to growth. This was slightly better than the consensus estimate of $14.02 billion. 17 July 2025
Pharmaceutical
Bayer is giving chief executive Bill Anderson more time to deliver on his ambitious efforts to reshape the German group, extending his contract by three years to March 2029. The move signals strong support from the company’s supervisory board, which voted unanimously in favor of the renewal. 17 July 2025
Biotechnology
UK pharma major GSK has gained US regulatory approval for a new prefilled syringe presentation of its shingles vaccine, Shingrix (zoster vaccine), a move aimed at streamlining administration and boosting immunization coverage. 17 July 2025
Pharmaceutical
Shares in US healthcare conglomerate Johnson & Johnson rose by 6% during Wednesday morning’s trading after the presentation of its second-quarter financial results and latest guidance for 2025. 16 July 2025
Biotechnology
Canada and USA-based oncology biotech Repare Therapeutics has entered into an exclusive worldwide licensing agreement with privately-held Swiss firm Debiopharm International to establish tomorrow’s standards of care to cure cancer and infectious diseases, for lunresertib, a first-in-class precision oncology PKMYT1 inhibitor. 16 July 2025
Pharmaceutical
Alnylam has secured expanded UK regulatory approval for Amvuttra (vutrisiran), broadening its indication to include treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults. 16 July 2025
Biotechnology
US pharma major AstraZeneca today released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase III clinical program showed that anselamimab, a light chain depleter antibody, did not achieve statistical significance for the primary endpoint compared to placebo in patients with Mayo stages IIIa and IIIb light chain (AL) amyloidosis. 16 July 2025
Latest In Brief for Alnylam Pharmaceuticals
Biotechnology
US biotech Nanoscope Therapeutics has begun a rolling submission to the American medicines regulator for MCO-010, the first gene-agnostic therapy seeking approval for retinitis pigmentosa (RP). 15 July 2025
Latest Relevant Ones To Watch News
Theratechnologies, a Canada-based biopharma, is to be acquired by CB Biotechnology, an affiliate of Future Pak, a privately-held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products. 4 July 2025
17 June 2025
16 June 2025
12 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze